Testosterone therapy and cardiovascular risk: a critical analysis of studies reporting increased risk
M Khera, M Miner, J Jaffe… - The journal of sexual …, 2021 - academic.oup.com
Background Treatment of “adult-onset hypogonadism”(AOH) with exogenous testosterone
therapy (TTh) to raise serum testosterone (T) levels may influence cardiovascular (CV) risk …
therapy (TTh) to raise serum testosterone (T) levels may influence cardiovascular (CV) risk …
Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk
M Khera, M Miner, J Jaffe, AW Pastuszak - The Journal of Sexual Medicine, 2021 - Elsevier
Background Treatment of “adult-onset hypogonadism”(AOH) with exogenous testosterone
therapy (TTh) to raise serum testosterone (T) levels may influence cardiovascular (CV) risk …
therapy (TTh) to raise serum testosterone (T) levels may influence cardiovascular (CV) risk …
Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk.
M Khera, M Miner, J Jaffe… - The Journal of Sexual …, 2020 - europepmc.org
Background Treatment of" adult-onset hypogonadism"(AOH) with exogenous testosterone
therapy (TTh) to raise serum testosterone (T) levels may influence cardiovascular (CV) risk …
therapy (TTh) to raise serum testosterone (T) levels may influence cardiovascular (CV) risk …
Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk
M Khera, M Miner, J Jaffe… - The journal of sexual …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Treatment of" adult-onset hypogonadism"(AOH) with exogenous testosterone
therapy (TTh) to raise serum testosterone (T) levels may influence cardiovascular (CV) risk …
therapy (TTh) to raise serum testosterone (T) levels may influence cardiovascular (CV) risk …